ANI Pharmaceuticals Inc
ANIP
View Detailed Chart
81.840USD
+0.340+0.42%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.84BMarket Cap
47.92P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.42%
5 Days
-0.01%
1 Month
+5.63%
6 Months
+18.45%
Year to Date
+3.67%
1 Year
+35.97%
View Detailed Chart
TradingKey Stock Score of ANI Pharmaceuticals Inc
Currency: USD Updated: 2026-02-06Key Insights
ANI Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 6 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 109.71.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ANI Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
ANI Pharmaceuticals Inc Highlights
StrengthsRisks
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 94.19% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 47.92, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 21.97M shares, increasing 0.07% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.30M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.66.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
109.714
Target Price
+34.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ANI Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ANI Pharmaceuticals Inc Info
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Ticker SymbolANIP
CompanyANI Pharmaceuticals Inc
CEOLalwani (Nikhil Suresh)
Websitehttps://www.anipharmaceuticals.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68446.920
-1523.210 (-2.18%)
282.580
+22.390 (+8.61%)
2032.060
-19.670 (-0.96%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
